CACNA2D4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL6121858	0.52	9/20
SCHEMBL2585915	0.51	8/20
SCHEMBL3354274	0.62	7/20
SCHEMBL3357851	0.54	7/20
SCHEMBL4750473	0.52	7/20
SCHEMBL3350921	0.49	7/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL5428566	0.52	6/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL4405461	0.55	5/20
SCHEMBL4399845	0.54	5/20
SCHEMBL4967687	0.51	5/20
SCHEMBL1810921	0.51	5/20
SCHEMBL4399843	0.50	5/20
SCHEMBL3477582	0.47	5/20
SCHEMBL3353571	0.47	5/20

Clinical trials — most relevant to CACNA2D4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vitamin D and Carboxy PTH Fragments in Coronary Calcification	PHASE4	WITHDRAWN
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI	PHASE2	COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
United States Hypophosphatasia Molecular Research Center	nan	COMPLETED
Osteogenic Profiling of Normal Calvarial Bone	nan	COMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study	nan	WITHDRAWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders	nan	UNKNOWN
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CACNA2D4 binder may also engage these)

Protein	Name	Similarity
Q9Z1L5	—	1.000	Q9Z1L5 →
Q5RJF7	—	1.000	Q5RJF7 →
Q8CFG5	—	1.000	Q8CFG5 →
CACNA2D3	Voltage-dependent calcium channel subunit alp	0.992	landscape →
A8XP97	—	0.988	A8XP97 →
P14617	—	0.986	P14617 →
Q9Z218	—	0.985	Q9Z218 →
Q75ZY9	—	0.985	Q75ZY9 →
Q2QLA9	—	0.985	Q2QLA9 →
Q8BG22	—	0.984	Q8BG22 →
Q09YK0	—	0.984	Q09YK0 →
Q07DZ1	—	0.984	Q07DZ1 →
P42658	—	0.984	P42658 →
P97523	—	0.984	P97523 →
Q108U6	—	0.984	Q108U6 →
Q80T41	—	0.984	Q80T41 →
P16056	—	0.983	P16056 →
O35312	—	0.983	O35312 →
Q2QLH6	—	0.983	Q2QLH6 →
O94910	—	0.983	O94910 →
O54861	—	0.983	O54861 →
O97817	—	0.983	O97817 →
O88307	—	0.983	O88307 →
Q91735	—	0.983	Q91735 →
Q28193	—	0.982	Q28193 →
Q5BI42	—	0.982	Q5BI42 →
O95393	—	0.982	O95393 →
EPHA5	Ephrin type-A receptor 5	0.982	landscape →
Q3U435	—	0.982	Q3U435 →
P12607	—	0.982	P12607 →